21 August 2025
21 August 2025
Pfizer says it is “confident” in the intellectual property for its billion-dollar Covid-19 pill Paxlovid.
The FDA has confirmed a pushback to target action dates for Eylea HD, a delay expected by Regeneron.
The agreement follows AnGes' announcement of the completion of clinical studies and plans to submit a BLA.
KER-065 fuses a modified ligand-binding domain from activin receptors IIA and IIB with the Fc domain of a human antibody.
As Novo Nordisk joins the US MASH market, Madrigal stretches Rezdiffra’s legs in the European market.
The FDA has requested that PTC run an additional study to prove vatiquinone’s efficacy prior to resubmission.
VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
